Vitamin K antagonist

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Warning label on a tube of "brown rat" poison laid on a dike of the Scheldt river in Steendorp, Belgium. The tube contains bromadiolone, a second-generation ("super-warfarin") anticoagulant. The label in Dutch states, in part: Contains an anticoagulant with prolonged activity. Antidote Vitamin K1.
Vitamin K2 (menaquinone). In menaquinone the side chain is composed of a varying number of isoprenoid residues.

Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. They are used as anticoagulant medications in the prevention of thrombosis, and in pest control, as rodenticides.

Mechanism of action[edit]

These drugs deplete the active form of the vitamin by inhibiting the enzyme vitamin K epoxide reductase and thus the recycling of the inactive vitamin K epoxide back to the active reduced form of vitamin K. The drugs are structurally similar to vitamin K and act as competitive inhibitors of the enzyme. The term "vitamin K antagonist" is a misnomer, as the drugs do not directly antagonise the action of vitamin K in the pharmacological sense, but rather the recycling of vitamin K.

Vitamin K is required for the proper production of certain proteins involved in the blood clotting process. For example, it is needed to carboxylate specific glutamic acid residues on prothrombin. Without these residues carboxylated, the protein will not form the appropriate conformation of thrombin, which is needed to produce the fibrin monomers that are polymerized to form clots.[1]

The action of this class of anticoagulants may be reversed by administering vitamin K for the duration of the anticoagulant's residence in the body, and the daily dose needed for reversal is the same for all drugs in the class. However, in the case of the second generation "super warfarins" intended to kill warfarin resistant rodents, the time of vitamin K administration may need to be prolonged to months, in order to combat the long residence time of the poison.[2]

The vitamin K antagonists can cause birth defects (teratogens).[3]

Coumarins (4-hydroxycoumarins)[edit]

Main article: 4-hydroxycoumarins

Coumarins (more accurately 4-hydroxycoumarins) are the most commonly used VKAs.

In medicine, the most commonly used VKA is warfarin.[4] Warfarin was initially used as a rodenticide, but made the transition to pharmaceutical. Eventually some rodents developed resistance to it. The "second generation" VKAs for dedicated use as rodenticides are sometimes called "super warfarins." These VKAs are enhanced to kill warfarin-resistant rodents. The enhancement to the molecule takes the form of a larger lipophilic group to enhance the fat solubility of the poison and greatly increase the time it acts within the animal's body.[5] However, as described above, the super-warfarins do not inhibit vitamin K and their effect is easily inhibited by vitamin K. Nevertheless, oral vitamin K may need to be given for times that may exceed a month, in order to counter the effect of second-generation VKAs that have very long residence times in the fat of animals and humans.

For a more complete list of coumarins used as pharmaceuticals and rodenticides, see the main article on 4-hydroxycoumarins.

Other VKAs[edit]

Not all VKAs are coumarins; many of the non-coumarin VKAs are 1,3-indandione derivatives.[citation needed] Although these are loosely termed VKAs, these molecules share a separate mechanism of action, inhibiting the enzyme vitamin K epoxide reductase.[citation needed] Such therapeutic agents may themselves be antagonized by administration of vitamin K.[citation needed] Examples include phenindione,[citation needed] Clorindione,[6] diphenadione,[citation needed] and fluindione.[7][non-primary source needed]

See also[edit]

References[edit]

  1. ^ Suttie, J. W. (July 1980). "Mechanism Of Action Of Vitamin K: Synthesis Of Y-Carboxyglutamic Acid". Critical Reviews in Biochemistry 8 (2): 191–223. doi:10.3109/10409238009105469. 
  2. ^ Olmos V, López CM (2007). "Brodifacoum Poisoning with Toxicokinetic Data". Clinical Toxicology 45 (5): 487–9. doi:10.1080/15563650701354093. PMID 17503253. 
  3. ^ Schaefer C, Hannemann D, Meister R, et al. (June 2006). "Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study". Thromb. Haemost. 95 (6): 949–57. doi:10.1160/TH06-02-0108. PMID 16732373. 
  4. ^ Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G (June 2008). "Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest 133 (6 Suppl): 160S–198S. doi:10.1378/chest.08-0670. PMID 18574265. 
  5. ^ Griminger P (July 1987). "Vitamin K antagonists: the first 50 years" (PDF). J. Nutr. 117 (7): 1325–9. PMID 3302140. 
  6. ^ https://books.google.com/books?id=0vXTBwAAQBAJ&q=Clorindione#v=snippet&q=Clorindione&f=false
  7. ^ Mentré F, Pousset F, Comets E, et al. (January 1998). "Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients". Clin. Pharmacol. Ther. 63 (1): 64–78. doi:10.1016/S0009-9236(98)90122-9. PMID 9465843. [non-primary source needed]

Further reading[edit]

  • Published reviews, 2011-2016, regarding Vitamin K antagonists.
  • Reynolds, Matthew R. (February 2013). "Discontinuation of Rivaroxaban: Filling in the Gaps" (editorial comment). J. Am. Coll. Cardiol. 61 (6): 659f. doi:10.1016/j.jacc.2012.09.056. Retrieved 5 April 2016. The authors'… most likely explanation for the observed risk in the post-study transition period is not that rivaroxaban has some property resulting in a rebound effect, but rather that the high-risk… ROCKET AF trial [patients]… had a substantial difference in anticoagulation coverage during this period, and the event rates merely reflect the unmasking of their underlying risk… / Although this explanation is fairly persuasive, the evidence that the post-study excess stroke risk in rivaroxaban patients was the result of inadequate VKA [vitamin K antagonist] therapy remains somewhat circumstantial. The INRs were not collected as carefully during the post-trial period… [and] the authors do not provide any information on the use of bridging therapies… with unfractionated or low–molecular-weight heparin… [which] was not mandated by the study protocol during either temporary interruptions or at the end of the study. The bleeding rates reported in the current study also are counterintuitive: if the excess strokes in rivaroxaban patients were the result of underanticoagulation in the post-trial period, then why did these patients also have a higher bleeding risk? The investigators will need to scrutinize this large trial database further to understand these issues more fully. 
  • Patel, Manesh R.; Anne S. Hellkamp; Yuliya Lokhnygina; Jonathan P. Piccini; Zhongxin Zhang; Surya Mohanty; Daniel E. Singer; Werner Hacke; Günter Breithardt; Jonathan L. Halperin; Graeme J. Hankey; Richard C. Becker; Christopher C. Nessel; Scott D. Berkowitz; Robert M. Califf; Keith A.A. Fox; & Kenneth W. Mahaffey (February 2013). "Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation: Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)". J. Am. Coll. Cardiol. 61 (6): 651–658. doi:10.1016/j.jacc.2012.09.057. Retrieved 5 April 2016. We undertook a post-hoc analysis of data from the ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation, n = 14,624) for stroke or non-CNS embolism within 30 days after temporary interruptions of 3 days or more, early permanent study drug discontinuation, and end-of-study transition to open-label therapy. / In atrial fibrillation patients who temporarily or permanently discontinued anticoagulation, the risk of stroke or non-CNS embolism was similar with rivaroxaban or warfarin. An increased risk of stroke and non-CNS embolism was observed in rivaroxaban-treated patients compared with warfarin-treated patients after the end of the study, underscoring the importance of therapeutic anticoagulation coverage during such a transition. 
  • Agnelli, Giancarlo (2005). "Foreword: Contemporary issues in the management and treatment of atrial fibrillation" (supplement foreword). European Heart Journal Supplements 7 (Supplement C, 14 April): C3f. doi:10.1093/eurheartj/sui013. Retrieved 5 April 2016. This supplement represents the first publication of Thrombosis Quorum (TQ), a recently established international consortium of multidisciplinary thrombosis-related specialists dedicated to raising the priority of thrombosis. TQ aims to address the unmet clinical needs in the prevention and treatment of thromboembolic conditions, and promote the optimum management of patients with or at risk of these disorders by providing a cross-disciplinary forum for information exchange and debate. This [issue] incorporates a collection of state-of-the-art articles written by the TQ Steering Group and co-authors, and in this instance, focuses on the management and treatment of patients with atrial fibrillation (AF).  Note, because this issue foreword is over a decade old, its statements regarding limited available oral anticoagulants is no longer accurate.